Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Politics

Russia restricts abortion drug sales until 2030

by October 5, 2023
October 5, 2023
Russia restricts abortion drug sales until 2030

The Russian government is tightening restrictions on access to abortion-inducing drugs.

Russia’s Ministry of Health announced Tuesday new limits on abortion drug distribution and sales at pharmacies. 

Misoprostol and mifepristone are specifically being targeted with the restrictions. The two drugs are now limited by subject-quantitative registration, according to translations from the Moscow Times. 

The restrictions will go into effect on Sep. 1, 2024 and last for exactly six years.

Health Minister Mikhail Murashko first suggested adding the two abortion drugs to the registry in July, saying they pose both medical and ethical risks for Russian women. 

Russia is currently experiencing a cultural shift in its attitudes toward abortion. Previously rather liberal on the issue, the country’s leadership and conservative communities have seized the current climate to propagate anti-abortion regulations. 

The Russian Orthodox Church — which enjoys a historically significant relationship with the nation’s politics — is also vehemently opposed to abortion on the basis of Christian morals.

Under the new restrictions, individuals seeking the drug will need to obtain a prescription from a doctor before purchasing. 

Additionally, medical providers will require a special license to provide the abortion-inducing medication to patients. 

Providers will also have to track and report their distribution of the drugs.

Timothy Nerozzi is a writer for Fox News Digital. You can follow him on Twitter @timothynerozzi and can email him at timothy.nerozzi@fox.com

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Biden says Dems, GOP ‘remain committed’ to bipartisan solutions following McCarthy ouster
next post
Steve Scalise, McCarthy’s longtime No. 2, announces bid for House speaker

Related Posts

Chemical abortion harms women. Supreme Court can’t ignore...

December 23, 2023

WATCH: Fox News Digital focus group voters raise...

June 28, 2024

McCarthy ally calls Gaetz an ‘a–hole’ as tensions...

October 4, 2023

Experts slam leaked UNRWA report claiming Israel coerced...

March 11, 2024

Sen. Paul says Fauci deserves prison for COVID-19...

January 16, 2024

Pharmacist GOP Rep Carter urges Biden to take...

June 25, 2024

Speaker Johnson launches bipartisan artificial intelligence ‘task force’

February 21, 2024

Longtime Democratic lawmaker turned activist defects to Republican...

July 21, 2023

DeSantis invites VP Harris to Florida to set...

August 1, 2023

‘We need to win’ AI race against Beijing,...

February 4, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    • S&P 500 Breaking Out Again: What This Means for Your Portfolio

    • Dana Samuelson: Gold, Silver in Global Bank Run, Prices on Hair Trigger

    • Mike Maloney: Gold, Silver Bull Run in Final Phase, I Expect “Spectacular” Prices

    • Editor’s Picks: Gold and Silver Prices Rise as Government Shutdown Ends, Then Pull Back

    • Gold’s Long Game: New Orleans Panelists See More Upside Ahead

    Categories

    • Business (1,410)
    • Investing (3,156)
    • Politics (3,699)
    • Stocks (1,852)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved